Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
Background Patients treated with immune checkpoint inhibitors (ICIs) may experience pseudoprogression, which can be classified as progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 and could lead to inappropriate treatment discontinuation. Immune-response criteri...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMJ Publishing Group
2022-02-01
|
| سلاسل: | Journal for ImmunoTherapy of Cancer |
| الوصول للمادة أونلاين: | https://jitc.bmj.com/content/10/2/e003302.full |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|